Kornimate/medical-research-clean huggingface dataset:
complications of transurethral resection of the bladder tumour

Conditions: Bladder Cancer

Summary: this is a prospective study enrolling consecutive patients who undergo transurethral resection of the bladder tumour (turbt) aimed at determination of a safety of the procedure. study end-points are incidence, severity and predictive factors of surgical complications. the study secondary aim is a validation of clavien dindo scoring system for reporting complication of turbt.


Eligibility criteria:
inclusion criteria: * primary or recurrent bladder tumour * informed consent to undergo the surgery exclusion criteria: * age \<18 years

Keywords: bladder cancer postoperative complications
fibroscan evaluating immunotherapy response in hepatocellular carcinoma

Conditions: Hepato Cellular Carcinoma (HCC)

Summary: the goal of this prospective cohort study is to evaluate the role of transient elastography (fibroscan) in predicting the response of immunotherapy in advanced hepatocellular carcinoma (hcc) patients. researchers will predict the response to 6 months of hcc immunotherapy regarding improvement of the degree of liver fibrosis, development of liver decompensation, complications, survival, and mortality. participants will undergo history-taking, clinical examination, laboratory investigations, child-pugh classification, model for end-stage liver disease (meld) score, bclc staging, abdominal ultrasonography, triphasic ct abdomen with contrast or mri (for evaluation of tumor site, size and number), and fibroscan examination at baseline and follow-up after 6 months.


Eligibility criteria:
inclusion criteria: * patients with confirmed advanced hcc (diagnosed by two imaging modalities or liver biopsy) eligible for immunotherapy. * patients with preserved liver function (compensated child-pugh a if there is underlying cirrhosis). * patients with performance status ≤2 at staging work-up. * absence of high-risk stigmata for bleeding on upper endoscopy, e.g. properly treated oesophageal varices and no history of variceal bleeding, in order to minimise bleeding risk. exclusion criteria: * prior locoregional therapy or liver transplantation. * child-pugh class c patients. * patients with performance status \>2 at staging work-up. * vascular disorders, arterial hypertension, and risk of variceal bleeding. * severe autoimmune disorders. * patients who lost follow-up. * pregnant or breastfeeding women. * unwilling to participate in our study.

Keywords: fibroscan immunotherapy liver stiffness hepatocellular carcinoma
tranexamic acid and blood clots in knee surgery

Conditions: Venous Thrombosis

Summary: this is an observational trial to estimate the incidence of deep vein thrombosis (dvt) in total knee replacement patients who received an intraoperative dose of tranexamic acid.

this study is anticipated to consist of 30 participants over 18 years of age scheduled for total knee arthroplasty at sandoval regional medical center with administered intraoperative tranexamic acid, who do not meet the exclusion criteria. the patients will be examined on postoperative day 1. lower-extremity ultrasound will be used to screen for deep vein thrombosis (dvt). incidence data for dvt will then be compared with the historical incidence rate at our institution for total knee arthroplasty without the use of tranexamic acid, which is approximately 12%. patients found on screening to have deep vein thrombosis will be referred for appropriate care.

Eligibility criteria:
inclusion criteria: * adult patients scheduled for total knee arthroplasty at sandoval regional medical center with an intraoperative dose of tranexamic acid exclusion criteria: * previous deep vein thrombosis or pulmonary embolism episode * known coronary artery disease or peripheral vascular disease * previously diagnosed hypercoagulable states (e.g. leiden factor v, antiphospholipid antibody, protein c or s deficiency) * pregnancy * creatinine clearance less than 30 ml/min * non-fluency in english
a trial of chronotherapy of corticosteroids in duchenne muscular dystrophy

Conditions: Duchenne Muscular Dystrophy (DMD)

Summary: duchenne muscular dystrophy (dmd) is a progressive neuromuscular disease for which no curative treatment has yet been identified, making it important to slow progression and improve the quality of life among affected boys and young men. treatment with corticosteroids is standard of care for patients with dmd five years old and older, due to the robust observation that this intervention lengthens the interval prior to loss of ambulation but is associated with many side effects. this clinical trial will be conducted in the youngest age group able to receive corticosteroids orally and on whom study outcomes are measurable, ages 3 to 7 years. this is a randomized, double blinded, double masked, placebo-controlled clinical trial that will explore whether better synchronization of corticosteroid administration with the circadian rhythm will provide improved tolerability and at least comparable efficacy to current standards in which corticosteroids are always given in the morning. furthermore, the trial provides a unique opportunity to rigorously evaluate corticosteroid effects in the young dmd patient, both for efficacy as compared to placebo and as a study of the impact of corticosteroid chronotherapy, or delayed release, on increased tolerability over standard therapy. the main hypothesis is that synchronization of the timing of corticosteroid dosing will improve medication tolerability in children, while maintaining (non-inferiority) the efficacy of corticosteroid. the study also offers a unique opportunity to measure several biomarkers as well as novel genetic modifiers that may further impact the response to corticosteroid in dmd.


Eligibility criteria:
inclusion criteria: * genetically confirmed dystrophin mutation compatible with dmd phenotype. specifically, gene deletion test positive (missing one or more exons) in the central rod domain (exons 25-60) of dystrophin, where reading frame can be predicted as 'out-of-frame' or showing complete absence of dystrophin by muscle biopsy. * ages between 3 years and \< 7 years * steroid-naïve * signed informed consent exclusion criteria: * treatment with coenzymeq10, creatine, amino acid supplements within 3 months of study entry * treatment with cardiac medications: beta-blockers, digoxin, and carvedilol * existing medical condition or physical disability that would alter subject's motor development * existing medical condition that precludes the use of corticosteroids * inability to swallow sample tablet in bite of soft food\* * investigator assessment that participant or family will not be compliant with treatment or study procedures * been on investigational dmd medication for the past 6 months

Keywords: duchenne muscular dystrophy corticosteroids
sport therapy and osteopathy manipulative treatment in als

Conditions: Amyotrophic Lateral Sclerosis

Summary: this project assessed muscle oxidative metabolism and fatigue in patients affected by amyotrophic lateral sclerosis (als) undergoing to three months of individualized cardiovascular and strength training. muscle oxidative metabolism and strength will be assessed by non-invasive methods, such as near-infrared spectroscopy (nirs) and mechanomyography (mmg). nirs is a technique giving indications on the capacity of oxygen extraction of muscles during exercise. mmg allows analyzing the pattern of motor unit recruitment and related fatigue. the investigators will also assess the effects of training on pain tolerance and quality of life (qol) by the brief pain inventory and the mcgill quality of life questionnaires, using the validated italian versions. patients will be assessed longitudinally before (time t0) and after three months of individualized training (time t1). after one month of de-training (time t2) the investigators will assess the hypothetic persistence of any treatment-related effect. the effect of three months-osteopathic treatment (osteo) on pain and qol will be assessed as well.

single blind pilot trial assessing the efficacy and side effects of active training or osteopathic manipulative treatment in als. interventions will be administered for three months (plus one month without intervention) by specialized personnel. primary outcome measures will include: exercise tolerance and muscle oxygen extraction capacity, side effects. secondary outcome measures will include: pain, qol and disease progression scales.

Eligibility criteria:
inclusion criteria: * diagnosis of als * early stages of disease * able to perform exercise with major muscle groups. exclusion criteria: * non-invasive ventilation (niv) * tracheostomy * coronaropathy * ongoing infectious diseases * cognitive deficits.

Keywords: amyotrophic lateral sclerosis sport therapy osteopathic manual treatment muscle oxidative metabolism
o2matic cardiology protocol

Conditions: Heart Diseases

Summary: automatic oxygen supply with the o2matic device has been shown to provided an enhanced oxygen treatment in patients with hypoxemia. o2matic was significantly better than manual control to maintain oxygen saturation within target interval and to reduce time with unintended hypoxemia in patients suffering from chronic obstructive pulmonary disease. this trial investigates the effect of using o2matic in hypoxic patients submitted to the department of cardiology.

oxygen supply to patients with cardiovascular disease has been subject to several investigations. both too much and too little oxygen is supposed to be harmful. the o2matic device is a new way of supplying oxygen treatment which is significantly better than manual control to maintain oxygen saturation within target interval and to reduce time with unintended hypoxemia. the device has past favorable tests in patients suffering from chronic obstructive pulmonary disease. this study investigates the application of the o2matic device on hypoxic patients admitted to the cardiology ward.

Eligibility criteria:
inclusion criteria: * patients with heart disease and an oxygen saturation below 94% admitted to the department of cardiology * age of 30 or more * intellectual capacity to participate in the trial * willing to give informed accept of participation in the trial. exclusion criteria: * unstable patients * need for ventilatory support except intermittent continuous positive airway pressure * fertile women (age\<55 years) with a positive pregnancy test * unable to participate due to language or cognitive problems

Keywords: hypoxemia cardiology automatic oxygen supply
genetics of central nervous system arteriovenous malformations (gene-mav)

Conditions: Arteriovenous Malformations

Summary: cerebral and medullary arteriovenous malformations (avms) lead to arterial and venous networks to communicate pathologically, creating an arteriovenous shunt. the occurrence of intracranial haemorrhage is the most important prognostic factor of avms because it is associated with a significant morbidity and mortality. the genetic, molecular and cellular mechanisms that cause vascular malformations of the central nervous system are partially known and the influence of genetic damage on the prognosis of avms is poorly known.

cerebral and medullary arteriovenous malformations (avms) are morphologically abnormal vessels located on the surface or in the cerebral or medullary parenchyma. these vascular lesions cause the arterial and venous networks to communicate pathologically, creating an arteriovenous shunt. the prevalence of cerebral cerebral and medullary avms in general population is difficult to establish given the rarity of the condition. however, it is estimated at around 1 per 10,000 inhabitants (0.01%). about 15-20% of the cerebral vascular accidents are asymptomatic at the time of diagnosis. the occurrence of intracranial haemorrhage is the most important prognostic factor because it is associated with a significant morbidity and mortality. the management of an avm is usually carried out in a multidisciplinary way, combining interventional neuroradiology, neurosurgery and vascular neurology. the genetic, molecular and cellular mechanisms that cause vascular malformations of the central nervous system are partially known. several recent research works highlight mutations in the ras-mapk or mapk-erk signalling pathway in avms. in cases of cerebral avms considered to be sporadic, a somatic kras/braf mutation has recently been demonstrated in tissue samples of operated avms. except in the case of hereditary haemorrhagic telangiectasia (hht or rendu-osler-weber syndrome), the influence of genetic damage on the prognosis of avm is poorly known. it is also interesting to note that genetic screening is not routinely performed in patients with cerebro-medullary avms and that therefore the prevalence of these clinical entities in patients with avms is not known.

Eligibility criteria:
inclusion criteria: * patient with a vascular malformation of the cerebral or medullary identified on diagnostic imaging (angio-ct, angio-mri or diagnostic angiography) for which clinical monitoring alone or intervention (endovascular treatment, surgery or radiosurgery) is planned in the centres participating in the research. exclusion criteria: * pregnant, parturient or breastfeeding woman
an evaluation of virtual reality in labor pain during vaginal childbirth

Conditions: An Evaluation of Virtual Reality in Labor Pain During Vaginal Childbirth

Summary: this study will be conducted to evaluate the effect of applying virtual reality among laboring women during first stage of labor

this study will be conducted to evaluate the effect of applying virtual reality among laboring women during first stage of labor

Eligibility criteria:
inclusion criteria: * age between 20-25 years old . * body mass index (bmi) 25- 32 kg/m2 . * primiparous . * highly educated. exclusion criteria: * laboring women with high risk pregnancy. * laboring women are taking pharmacological methods to relieve pain during first stage of labor. * low educated women
vocal intervention in systemic sclerosis

Conditions: Systemic Sclerosis

Summary: systemic sclerosis is a systemic connective tissue disease with physical and mental disturbances. based on a pilot study the feasibility and effectiveness of a novel, self-developed concept of vocal intervention in systemic sclerosis under vocal pedagogical guidance and music therapy is assessed.

this concept aims at functional improvement of respiration and mouth-opening, enhancement of quality of life, and reduction of stress carried out by a music therapist and singer with pedagogical formation.

Eligibility criteria:
inclusion criteria: * positive criteria for systemic sclerosis according to the american college of rheumatology/european league against rheumatism exclusion criteria: * affection of the vocal apparatus * dyspnea at rest * oxygen prescription
antidfs70 lupus nephritis

Conditions: Systemic Lupus Erythematosus

Summary: systemic lupus erythematous (sle) is a heterogeneous autoimmune disease that involve many different organs and display a variable clinical course. the prevalence of sle varies across gender, race/ethnicity, and geographic regions. sle demonstrates a striking female predominance with a peak incidence of disease during the reproductive years. in adults, the female to male ratio is 10- 15:1(1)( 2) clinical features in individual patients can be quite variable and range from mild joint and skin involvement to severe, life-threatening internal organ disease. constitutional symptoms, rash, mucosal ulcers, inflammatory polyarthritis, photosensitivity, and serositis are the most common clinical features of the disease. (3) (4) anti-dfs70 antibodie) and their clinical associations remain an immunological paradox. unlike other antinuclear antibodies , there is a growing body of evidence that anti-dfs70 antibodies, when present in high titers and in isolation (without accompanying other antibodies), are useful to aid in the exclusion of antinuclear antibodies associated rheumatic diseases. (8) anti-dfs70 antibodies were not associated with lupus nephritis development in systemic lupus erythematosus patients but were associated with anti-dsdna antibodies , proliferative lupus nephritis, and renal activity index . this suggests their potential to serve as a non-histological biomarker for lupus nephritis subclass and activity status. (8)


Eligibility criteria:
inclusion criteria: 1. patients who fulfill the 2019 american college of rheumatology/european league against rheumatism classification criteria of systemic lupus erythematous . (9) 2. patients who is able to give informed consent to join the study. • exclusion criteria: - - any patient with any collagen disease other than systemic lupus erythematous
interferon gamma with peg-interferon alpha 2a and ribavirin in non responders patients with chronic hepatitis c

Conditions: Hepatitis C, Chronic

Summary: viral hepatitis c is treated with peg-interferon alpha 2a/2b and ribavirin. there is no treatment recommended for non responders patients. this study will evaluate the efficacy, after a second treatment with peg-interferon alpha 2a and ribavirin for 12 weeks of the addition of interferon gamma in non responders patients

viral hepatitis c is treated with peg-interferon alpha 2a/2b and ribavirin for 24 weeks. in many patients, there is no efficacy of this treatment on hepatitis c, and there is no treatment recommended for them. interferon gamma has anti-infectious and anti-fibrosis activity. this study will evaluate the effect, after a second treatment with peg-interferon alpha 2a and ribavirin for 12 weeks, of the addition of interferon gamma in non responders patients. 65 patients will be included in order to include 27 patients who are non responders after 12 weeks of a second treatment and are eligible to receive interferon gamma. patients will then receive peg-interferon alpha 2a (180 micro g once a week, by injection), ribavirin (1,000 to 1,200 mg per day, according to weight) and interferon gamma (100 micro g thrice a week, by injection) during 8 months

Eligibility criteria:
inclusion criteria: * positive anti-hcv antibodies * positive hcv rna (quantitative method) * previous treatment with peg-interferon alpha 2b 1.0 to 1.5 micro g/kg (during at least 12 weeks) with ribavirin (at least 800 mg/day during at least 12 weeks),stopped since at least 3 months * without lower dosage during previous treatment * non responder to the previous treatment with peg-interferon alpha 2b and ribavirin, with detectable hcv rna at w24 or decrease of less than 2 log10 copies/ml at w12 or decrease greater than 2 log10 but detectable hcv rna * metavir over f2 on the most recent biopsy * alt increase over normal value twice during last 6 months exclusion criteria: * hiv infection * psychiatric pathology * alcool consummation * cirrhosis * pregnancy or plan of pregnancy * breastfeeding

Keywords: hepatitis c, chronic interferon alfa-2a ribavirin interferon-gamma, recombinant
outcome of radiation therapy in operated gastric cancer

Conditions: Gastric Adenocarcinoma

Summary: * study tolerability and toxicity of radiotherapy with or without chemotherapy for operated gastric cancer. * evaluate the efficacy of adjuvant radiotherapy with or without chemotherapy as regarding local control and overall survival.


Eligibility criteria:
inclusion criteria: * age of the patient; ≥18 and ≤75 years. * histologically proven gastric or gastroesophageal adenocarcinoma. * pt received adjuvant radiotherapy with or without chemotherapy with any protocol. exclusion criteria: * patient \>75 years\&\<18 years. * histologically types other than adenocarcinoma . * metastatic patients (m1). * pt didn't recive radiotherapy.
socioeconomic status, secondary prevention activities and recurrence after a myocardial infarction

Conditions: Socioeconomic Status; Secondary Prevention; Myocardial Infarction; Cardiovascular Disease; Stroke

Summary: this is a nationwide cohort study on real-world patients (n≈30,000) surviving a first myocardial infarction (mi) 2006-2013 and alive to attend a routine 1-year follow-up. associations between socioeconomic status (ses) and secondary preventive actions (spas) throughout the first year is studied and assessed as possible mechanisms underlying the increased risk of a first recurrent hard cardiocvascular (cv) outcome, recurrent atherosclerotic cardiovascular disease (rascvd), in patients with low socioeconomic status during long-term follow-up (2006-2018).


Eligibility criteria:
inclusion criteria: * swedish resident * alive and registered in the swedish websystem for enhancement and development of evidence based care in heart disease evaluated according to recommended therapies (swedeheart)'s secondary prevention subregistry between 1 january 2006 and 31 december 2013 at the 1-year-revisit exclusion criteria: * age \>76 years at baseline * missing data for disposable household income * history of mi, stroke, coronary artery bypass graft (cabg), or percutaneous coronary intervention (pci) prior to the index mi * not present in initial care registry (rikshia) * date of index mi before 2004 or missing * revisit outside 13±2 month window post-mi
couple-based mindfulness intervention for metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: the overall objective of this study is to develop a novel couple-based mindfulness intervention aimed at reducing distress in patients with metastatic colorectal cancer (mcrc) and their partners.

the overall objective of this study is to develop a novel couple-based mindfulness intervention aimed at reducing distress in patients with metastatic colorectal cancer (mcrc) and their partners. the intervention is named "mind-together" (mindfully navigating distress together). mind-together will be the first mindfulness-based intervention designed to reduce mcrc couples' distress by targeting their unique psychosocial needs. the intervention is projected to be a 4-session intervention delivered by a trained therapist to individual couples facing mcrc (i.e., a patient and his/her intimate partner) via video-conference (e.g., zoom).

Eligibility criteria:
patient inclusion criteria: * provision to sign and date the consent form. * stated willingness to comply with all study procedures and be available for the duration of the study. * be aged \> 18 years. * fluent in english language * be a person (i.e., patient) diagnosed with metastatic colorectal cancer (mcrc), a partner (e.g., spouse) of someone diagnosed with mcrc, or a clinician who treats patients diagnosed with mcrc. additional patient participant inclusion criteria: * has a current diagnosis of metastatic (stage iv, recurrent) colorectal cancer * has an ecog status \<2 or otherwise deemed appropriate for study participation by a clinician * is in a committed relationship with a romantic partner for \>6 months * has access to computer/internet through with video-conferencing (phone, laptop, tablet, desktop computer) * indicates a score \>0 on the distress thermometer additional partner participant inclusion criteria: * has been in a committed relationship \>6 months with a patient who meets the above eligibility criteria * has access to computer/internet through with video-conferencing (phone, laptop, tablet, desktop computer) * indicates a score \>0 on the distress thermometer additional clinician participant inclusion criteria: ∙is a physician or advanced practice clinician (e.g., oncologist, nurse practitioner, physician assistant, psychologist, mental health provider, etc.) exclusion criteria: ∙has a serious mental illness (e.g., psychotic disorder), cognitive impairment (e.g., dementia), or medical condition (e.g., significant impaired sight/hearing) that would compromise participation